Valve-in-Valve Transcatheter Aortic Valve Replacement and Bioprosthetic Valve Fracture Comparing Different Transcatheter Heart Valve Designs: An Ex Vivo Bench Study.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
14 01 2019
Historique:
received: 06 08 2018
revised: 04 10 2018
accepted: 23 10 2018
entrez: 10 1 2019
pubmed: 10 1 2019
medline: 19 12 2019
Statut: ppublish

Résumé

The authors assessed the effect of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) followed by bioprosthetic valve fracture (BVF), testing different transcatheter heart valve (THV) designs in an ex vivo bench study. Bioprosthetic valve fracture can be performed to improve residual transvalvular gradients following VIV TAVR. The authors evaluated VIV TAVR and BVF with the SAPIEN 3 (S3) (Edwards Lifesciences, Irvine, California) and ACURATE neo (Boston Scientific Corporation, Natick, Massachusetts) THVs. A 20-mm and 23-mm S3 were deployed in a 19-mm and 21-mm Mitroflow (Sorin Group USA, Arvada, Colorado), respectively. A small ACURATE neo was deployed in both sizes of Mitroflow tested. VIV TAVR samples underwent multimodality imaging, and hydrodynamic evaluation before and after BVF. A high implantation was required to enable full expansion of the upper crown of the ACURATE neo and allow optimal leaflet function. Marked underexpansion of the lower crown of the THV within the surgical valve was also observed. Before BVF, VIV TAVR in the 19-mm Mitroflow had high transvalvular gradients using either THV design (22.0 mm Hg S3, and 19.1 mm Hg ACURATE neo). After BVF, gradients improved and were similar for both THVs (14.2 mm Hg S3, and 13.8 mm Hg ACURATE neo). The effective orifice area increased with BVF from 1.2 to 1.6 cm BVF performed after VIV TAVR results in improved residual gradients. Following BVF, residual gradients were similar irrespective of THV design. Use of a small ACURATE neo for VIV TAVR in small (≤21 mm) surgical valves may be associated with challenges in achieving optimum THV position and expansion. BVF could be considered in selected clinical cases.

Sections du résumé

OBJECTIVES
The authors assessed the effect of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) followed by bioprosthetic valve fracture (BVF), testing different transcatheter heart valve (THV) designs in an ex vivo bench study.
BACKGROUND
Bioprosthetic valve fracture can be performed to improve residual transvalvular gradients following VIV TAVR.
METHODS
The authors evaluated VIV TAVR and BVF with the SAPIEN 3 (S3) (Edwards Lifesciences, Irvine, California) and ACURATE neo (Boston Scientific Corporation, Natick, Massachusetts) THVs. A 20-mm and 23-mm S3 were deployed in a 19-mm and 21-mm Mitroflow (Sorin Group USA, Arvada, Colorado), respectively. A small ACURATE neo was deployed in both sizes of Mitroflow tested. VIV TAVR samples underwent multimodality imaging, and hydrodynamic evaluation before and after BVF.
RESULTS
A high implantation was required to enable full expansion of the upper crown of the ACURATE neo and allow optimal leaflet function. Marked underexpansion of the lower crown of the THV within the surgical valve was also observed. Before BVF, VIV TAVR in the 19-mm Mitroflow had high transvalvular gradients using either THV design (22.0 mm Hg S3, and 19.1 mm Hg ACURATE neo). After BVF, gradients improved and were similar for both THVs (14.2 mm Hg S3, and 13.8 mm Hg ACURATE neo). The effective orifice area increased with BVF from 1.2 to 1.6 cm
CONCLUSIONS
BVF performed after VIV TAVR results in improved residual gradients. Following BVF, residual gradients were similar irrespective of THV design. Use of a small ACURATE neo for VIV TAVR in small (≤21 mm) surgical valves may be associated with challenges in achieving optimum THV position and expansion. BVF could be considered in selected clinical cases.

Identifiants

pubmed: 30621980
pii: S1936-8798(18)32212-X
doi: 10.1016/j.jcin.2018.10.043
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-75

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Janarthanan Sathananthan (J)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Stephanie Sellers (S)

Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada; Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Aaron M Barlow (AM)

Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada.

Viktória Stanová (V)

Aix-Marseille Univ, IFSTTAR, LBA UMR_T24, Marseille, France.

Rob Fraser (R)

ViVitro Labs Inc., Victoria, British Columbia, Canada.

Stefan Toggweiler (S)

Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland.

Keith B Allen (KB)

Saint Luke's Hospital, St. Luke's Mid America Heart Institute, Kansas City, Missouri.

Adnan Chhatriwalla (A)

Saint Luke's Hospital, St. Luke's Mid America Heart Institute, Kansas City, Missouri.

Dale J Murdoch (DJ)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; University of Queensland, Brisbane, Australia.

Mark Hensey (M)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Karen Lau (K)

Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada; Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Abdullah Alkhodair (A)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Danny Dvir (D)

University of Washington, Seattle, Washington.

Anita W Asgar (AW)

Montreal Heart Institute, Montreal, Quebec, Canada.

Anson Cheung (A)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Philipp Blanke (P)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

Jian Ye (J)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Régis Rieu (R)

Aix-Marseille Univ, IFSTTAR, LBA UMR_T24, Marseille, France.

Phillippe Pibarot (P)

Quebec Heart & Lung Institute, Laval University, Quebec, Canada.

David Wood (D)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Jonathan Leipsic (J)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Department of Radiology, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

John G Webb (JG)

Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: johngraydonwebb@gmail.com.

Articles similaires

Failed radial head arthroplasty treated by removal of the implant.

Juan Ameztoy Gallego, Blanca Diez Sanchez, Afonso Vaquero-Picado et al.
1.00
Humans Male Female Middle Aged Range of Motion, Articular
Humans Arthroplasty, Replacement, Shoulder Male Female Retrospective Studies

Hemiarthroplasty in young patients.

Hazimah Mahmud, Dong Wang, Andra Topan-Rat et al.
1.00
Humans Male Hemiarthroplasty Middle Aged Aged
Silicon Dioxide Water Hot Temperature Compressive Strength X-Ray Diffraction

Classifications MeSH